Elucidation of TMEPAI family-mediated inhibitory mechanism for YAP activity

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K16360
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
• Research Institution: Showa Pharmaceutical University
• Principal Investigator: Nakano Naoko 昭和薬科大学, 薬学部, 助教 (50733218)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: TMEPAIファミリー / TMEPAI / C18ORF1 / YAP / 悪性中皮腫

Outline of Final Research Achievements

We have already got the results that both YAP and TGF-β signals can be inhibited by TMEPAI family (particularly C18ORF1). In this study, we focused on how TMEPAI family inhibits YAP signal in detail. As results, the overexpression of C18ORF1 in mesothelioma cells exhibited inhibition of cell proliferation and colony formation. Therefore, we showed that TMEPAI family including C18ORF1 is capable of suppressing tumorigenicity of malignant mesothelioma cells although we could not address TMEPAI family-mediated inhibitory mechanism for YAP signal in detail.

Free Research Field

TGF-βシグナルとがん

Academic Significance and Societal Importance of the Research Achievements

悪性中皮腫細胞にC18ORF1を高発現させると、細胞増殖能が抑制された。また、軟寒天培地を用いたコロニー形成アッセイにおいてもC18ORF1を高発現させることによって悪性中皮腫細胞によるコロニー形成能が抑制された。これらの結果は、C18ORF1によって悪性中皮腫細胞の進展を抑制できる可能性を示唆している。したがって、C18ORF1によるYAP活性抑制メカニズムを明らかにできれば、YAPの活性化が報告されている悪性中皮腫だけでなく、他のYAPの活性化が原因となっている疾患に対する新規治療薬の開発の礎となる。